Evidence map›Paper›PMID 38054619›Full record

ArticleTransfusion2024

Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS-CoV-2 infection and vaccination.

Nareg H Roubinian, John Greene, Vincent X Liu, Catherine Lee, Dustin G Mark, David R Vinson, Bryan R Spencer, Roberta Bruhn, Marjorie Bravo, Mars Stone and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Transfusion, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Nareg H RoubinianKaiser Permanente Northern California Division of Research, Oakland, California, USA.
John GreeneKaiser Permanente Northern California Division of Research, Oakland, California, USA.ORCID 0000-0002-0859-6828
Vincent X LiuKaiser Permanente Northern California Division of Research, Oakland, California, USA.
Catherine LeeKaiser Permanente Northern California Division of Research, Oakland, California, USA.
Dustin G MarkKaiser Permanente Northern California Division of Research, Oakland, California, USA.
David R VinsonKaiser Permanente Northern California Division of Research, Oakland, California, USA.
Bryan R SpencerAmerican Red Cross, Scientific Affairs, Dedham, Massachusetts, USA.ORCID 0000-0002-9008-9154
Roberta BruhnVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0002-5898-8168
Marjorie BravoVitalant, Scottsdale, Arizona, USA.
Mars StoneVitalant Research Institute, San Francisco, California, USA.
Brian CusterVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-6251-366X
Steve KleinmanUniversity of British Columbia, Vancouver, British Columbia, Canada.
Michael P BuschVitalant Research Institute, San Francisco, California, USA.
Philip J NorrisVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0003-0526-2088
NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-P (REDS-IV)
Kaiser Permanente · USUniversity of California, San Francisco · USAmerican Red Cross · USUniversity of British Columbia · CAVitalant · US

Funding

(REDS-IV-P) RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY IV-DATA75N92019D00032 · NHLBI · WESTAT, INC. · PI CHAPMAN, KATHY · 2019 to 2025
$19.6M
REDS-IV-P - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) - SARS-CoV-2/COVID-19 STUDIES75N92019D00033 · NHLBI · VITALANT · PI NORRIS, PHILIP J. · 2019 to 2024
$15.6M
(REDS-IV-P) RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY IV-DOMESTIC HUBS75N92019D00034 · NHLBI · VITALANT · PI CUSTER, BRIAN · 2020 to 2024
$5.3M
NHLBI NIH HHS 75N92019D00032NHLBI NIH HHS 75N92019D00033NHLBI NIH HHS 75N92019D00034NHLBI NIH HHS HHSN 75N92019D00032NHLBI NIH HHS HHSN 75N92019D00033
6 · The paper itself

Abstract

backgroundThe safety of transfusion of SARS-CoV-2 antibodies in high plasma volume blood components to recipients without COVID-19 is not established. We assessed whether transfusion of plasma or platelet products during periods of increasing prevalence of blood donor SARS-CoV-2 infection and vaccination was associated with changes in outcomes in hospitalized patients without COVID-19.

methodsWe conducted a retrospective cohort study of hospitalized adults who received plasma or platelet transfusions at 21 hospitals during pre-COVID-19 (3/1/2018-2/29/2020), COVID-19 pre-vaccine (3/1/2020-2/28/2021), and COVID-19 post-vaccine (3/1/2021-8/31/2022) study periods. We used multivariable logistic regression with generalized estimating equations to adjust for demographics and comorbidities to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

resultsAmong 21,750 hospitalizations of 18,584 transfusion recipients without COVID-19, there were 697 post-transfusion thrombotic events, and oxygen requirements were increased in 1751 hospitalizations. Intensive care unit length of stay (n = 11,683) was 3 days (interquartile range 1-5), hospital mortality occurred in 3223 (14.8%), and 30-day rehospitalization in 4144 (23.7%). Comparing the pre-COVID, pre-vaccine and post-vaccine study periods, there were no trends in thromboses (OR 0.9 [95% CI 0.8, 1.1]; p = .22) or oxygen requirements (OR 1.0 [95% CI 0.9, 1.1]; p = .41). In parallel, there were no trends across study periods for ICU length of stay (p = .83), adjusted hospital mortality (OR 1.0 [95% CI 0.9-1.0]; p = .36), or 30-day rehospitalization (p = .29). DISCUSSION: Transfusion of plasma and platelet blood components collected during the pre-vaccine and post-vaccine periods of the COVID-19 pandemic was not associated with increased adverse outcomes in transfusion recipients without COVID-19.

Indexed as

Blood Component TransfusionBlood DonorsCOVID-19Platelet TransfusionAdultCOVID-19 VaccinesHospitalizationHumansOxygenPlasmaRetrospective StudiesVaccinationCOVID-19 VaccinesOxygen

Identifiers

PMID38054619
PMCPMC10842807
OpenAlexW4389390857

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.